Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Neuropsychopharmacology. 2008 Sep;33(10):2467-73. doi: 10.1038/sj.npp.1301628. Epub 2008 Jan 16.

Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study.

Author information

  • 1Department of Psychiatry, ORYGEN Research Centre, University of Melbourne, Parkville, Australia. bergerg@mac.com

Erratum in

  • Neuropsychopharmacology. 2009 Jan;34(2):535.

Abstract

Ethyl-eicosapentaenoic acid (E-EPA) is an omega-3 fatty acid that has been used in a range of neuropsychiatric conditions with some benefits. However, its mechanism of action is unknown. Here, we investigate its effects on in vivo brain metabolism in first-episode psychosis (FEP). Proton magnetic resonance spectroscopy at 3 T was performed in the temporal lobes of 24 FEP patients before and after 12 weeks of treatment in the context of a larger double-blind, placebo-controlled E-EPA augmentation study. Treatment group effects for glutathione (F1,12=6.1, p=0.03), and a hemisphere-by-group interaction for glutamine/glutamate (F1,20=4.4, p=0.049) were found. Glutathione increased bilaterally and glutamate/glutamine increased in the left hemisphere following E-EPA administration. Improvement in negative symptoms correlated with metabolic brain changes, particularly glutathione (r=-0.57). These results suggest that E-EPA augmentation alters glutathione availability and modulates the glutamine/glutamate cycle in early psychosis, with some of the metabolic brain changes being correlated with negative symptom improvement. Larger confirmatory studies of these postulated metabolic brain effects of E-EPA are warranted.

PMID:
18199999
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk